Clinical Trial Update: VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of Velcade (bortezomib) plus Rituximab for follicular non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: Gruppo Italiano Studio Linfomi | Conditions: Non Hodgkin's Follicular Lymphoma | Phase 2 | Status: COMPLETED